上海医药(601607.SH):重组抗CD20人源化单克隆抗体皮下注射液临床试验申请获受理
格隆汇11月30日丨上海医药(601607.SH)公布,近日,公司全资子公司上海交联药物开发的“重组抗CD20人源化单克隆抗体皮下注射液”临床试验申请获国家药监局受理。
重组抗CD20人源化单克隆抗体皮下注射液是新型人用重组单克隆抗体制品,上海交联药物具有自主知识产权,拟用于CD20阳性的B细胞非霍奇金淋巴瘤的治疗。该项目于2018年10月启动立项,2020年8月完成临床前研究,并向国家药监局提交临床试验申请。截至目前,该项目已累计投入研发费用约4,676万元人民币。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.